Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 39   

Articles published

PSTI 2.85 -0.01 (-0.35%)
price chart
Pluristem Therapeutics Investor Breakfast Webcast At 8:00 AM ET
Pluristem Therapeutics Investor Breakfast Webcast At 8:00 AM ET. By RTT News, July 23, 2014, 07:00:00 AM EDT. A A A. Vote up. loading.
Short Interest in Pluristem Therapeutics Declines By 22.1% (PSTI)  Watch List News (press release)
Related articles »  
Pluristem Therapeutics Sees Significant Decrease in Short Interest (PSTI)
The company reported ($0.14) earnings per share for the quarter, meeting the analysts' consensus estimate of ($0.14). Analysts expect that Pluristem Therapeutics will post $-0.60 EPS for the current fiscal year.
Pluristem to Host Investor Breakfast and Webcast on July 23 in New York City  MarketWatch
Related articles »  
New Lows: Pluristem Therapeutics (NASDAQ:PSTI), Baxano Surgical Inc ...
On 20 JUNE Pluristem Therapeutics Inc. (NASDAQ:PSTI) reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14).
Israel's Ministry of Health Approves Pluristem's Commercial-Scale 3D Cell ...
Pluristem Therapeutics Inc . (NASDAQ:PSTI) (tase:PLTR), a leading developer of placenta-based cell therapies, announced today that it has completed the approval process and received final clearance from a fifth regulatory agency for its 3D cell therapy ...
Related articles »  
Biotech New Lows; Kite Pharma Inc (NASDAQ:KITE), RXi Pharmaceuticals Corp ...
On july 9, Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced that it has initiated a phase II trial in South Korea to evaluate PLacental eXpanded (PLX) cells for the treatment of intermittent claudication (IC.
Related articles »  
Healthcare New lows: Signal Genetics (NASDAQ:SGNL), Parnell ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) a leading developer of placenta-based cell therapies, announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent claudication ...
Related articles »  
Pluristem Initiates South Korean Arm of Multinational Phase II Intermittent ...
Pluristem Therapeutics Inc . (NASDAQ:PSTI) (tase:PLTR), a leading developer of placenta-based cell therapies, today announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of ...
Related articles »  
Pluristem Initiates Trial in South Korea - Analyst Blog
Pluristem develops placenta-based cell therapies in collaboration with companies like United Therapeutics ( UTHR ) or through research and clinical institutions.
Related articles »  
United Therapeutics' (UTHR) CEO Martine Rothblatt on Q2 2014 Results ...
Remarks today concerning United Therapeutics Corporation will include forward-looking statements, representing the company's expectations or beliefs regarding future events. ..... The one which I think you're probably maybe most familiar with is our ...
Related articles »  
NIH's Human Placenta Project Is Validation For Placental Cells Curing Deadly ...
Pluristem Therapeutics, Inc. (PSTI), whose research and clinical work revolves around regenerative medicine based on special placental cells, could become a central figure in the Project.